The findings of a recent retrospective study may alleviate some of the concerns patients and physicians have had about Revlimid and the risk of secondary cancers.

The study found that the risk of developing a secondary cancer as a result of treatment with Revlimid occurred mainly when a patient had been treated with oral melphalan at the same time as Revlimid.

Revlimid (lenalidomide) did not appear to be associated with an in­creased risk of secondary cancers when administered together with

The year 2013 is likely to be remembered as a very good year when it comes to re­search related to multiple myeloma.

Previous years have witnessed re­search shedding new light on existing my­e­lo­ma ther­a­pies, as well as addi­tional re­search about poten­tial new ther­a­pies.

But, in the past, most of the im­por­tant new ther­a­pies that were being re­searched were from existing classes of ther­apy, making them less likely to offer dramatic im­prove­ments in the treat­ment of the dis­ease.

In 2013, not …

Each year, The Myeloma Beacon publishes many news articles sum­ma­rizing the latest research findings about multiple myeloma.  As in recent years, 2013 was a year filled with important multiple myeloma-related news.

During 2013, a new drug, Pomalyst, was approved for the treatment of multiple myeloma; researchers presented new findings about other potential new treat­ments; experts learned more about the factors that influence a patient’s prog­no­sis and reported improvements in survival over the past decade; the role of stem cell trans­planta­tion and …

At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster pre­sen­ta­tions about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.

Many of the presentations were about studies of Pomalyst (poma­lido­mide, Imnovid) and dex­a­meth­a­sone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (car­filz­o­mib), cla­rith­ro­my­cin (Biaxin), cyclo­phos­pha­mide (Cytoxan), …

More than twenty presentations about studies involving Pomalyst were pre­sented at this year’s meeting of the American Society of Hematology (ASH), which took place last month.

Several of these presentations were about the Phase 3 clinical trial that found Pomalyst (pomalidomide, Imnovid) plus low-dose dex­a­meth­a­sone (Decadron) significantly improved overall survival of relapsed and re­frac­to­ry myeloma pa­tients compared to high-dose dex­a­meth­a­sone alone (see related Beacon news).  This is the study that led to the ap­prov­al of pomalidomide …

Initial results from a Phase 1 clin­i­cal trial show prom­ise for SAR650984 as a thera­peutic option for heavily pre­treated multiple myeloma patients.

SAR650984 is one of several poten­tial new anti-myeloma agents for which clin­i­cal results were first pre­sented at the American Society of Hematology (ASH) meeting last week.

The results were pre­sented by Dr. Joseph Mikhael from the Mayo Clinic in Scottsdale, Arizona, who told The Beacon, “This drug was hands down the most promising new agent at ASH for …

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treat­ment options for newly diag­nosed, re­lapsed and …